Tabula Rasa HealthCare Reports Second Quarter 2023 Financial Results
- Continued strong organic revenue growth of 24%
- Second quarter adjusted EBITDA of $6.3 million increased more than 3x compared to Q2 2022
- None.
Continued Strong Organic Revenue Growth of
Second Quarter Adjusted EBITDA of
Highlights from the second quarter ended June 30, 2023 include:
- Second quarter revenue from continuing operations of
increased$90.0 million 24% , including medication revenue growth of25% and technology-enabled solutions revenue growth of22% versus the prior year second quarter. - Second quarter GAAP net loss and adjusted EBITDA from continuing operations of
and$9.7 million .3 million, respectively, compares with$6 and$12.7 million in the second quarter of 2022.$2.1 million
"We delivered another impressive quarter demonstrating the strength of the underlying organic growth in our core PACE market and our commitment to significantly improve profitability. This is a testament to the strong performance by our employees who remain focused on serving the most complex and vulnerable individuals in PACE and other value-based care models," said Brian Adams, President and Chief Executive Officer.
Key Financial Results | ||||||||||||
(in millions except percentages) | ||||||||||||
Q2 | Q2 2023 | |||||||||||
2023 | 2022 | % Change | Guidance | |||||||||
Revenue from continuing operations | $ | 90.0 | $ | 72.6 | 24 | % | $ | 88.0 - 90.0 | ||||
Gross margin | 25.0 % | 22.0 % | ||||||||||
Adjusted gross margin | 25.6 % | 23.1 % | ||||||||||
GAAP net loss from continuing operations | $ | (9.7) | $ | (12.7) | 23 | % | ||||||
Adjusted net income (loss) from continuing operations | $ | 0.7 | $ | (2.7) | 127 | % | ||||||
Adjusted EBITDA from continuing operations | $ | 6.3 | $ | 2.1 | 207 | % | $ | 3.5 - 4.5 |
Second Quarter 2023 Financial Results
All comparisons, unless otherwise noted, are to the three months ended June 30, 2022, and reflect continuing operations.
- Revenue – Revenue of
increased$90.0 million 24% compared to in the second quarter of 2022 and increased$72.6 million 2% as compared to the first quarter of 2023. Medication revenue of increased$69.6 million 25% due to continued PACE census growth and higher revenue per PACE participant. Technology-enabled solutions revenue of increased$20.4 million 22% compared to in the second quarter of 2022 and increased$16.7 million 5% as compared to the first quarter of 2023. - Gross Profit – Gross profit (exclusive of depreciation and amortization) of
($22.5 million 25.0% of revenue) increased41% as compared to ($16.0 million 22.0% of revenue) in the second quarter of 2022. Adjusted gross profit of ($23.0 million 25.6% of revenue) increased37% as compared to ($16.8 million 23.1% of revenue) a year ago. Both medication and technology-enabled solutions gross margins increased vs. the year-ago period, driven by increased scale and operating efficiency improvements. - GAAP Net Loss – GAAP net loss from continuing operations of
decreased as compared to a net loss of$9.7 million in the second quarter of 2022. GAAP net loss from discontinued operations (net of tax) of$12.7 million compared to a net loss of$0.1 million in the second quarter of 2022. The second quarter of 2022 included the PrescribeWellness, SinfoníaRx and DoseMe businesses. As previously announced on March 2, 2023, TRHC completed the sales of SinfoníaRx and DoseMe during the first quarter of 2023.$36.9 million - Adjusted EBITDA – Adjusted EBITDA from continuing operations of
million ($6.3 7.0% of revenue) increased207% vs. ($2.1 million 2.8% of revenue) in the second quarter of 2022. The improvement vs. the prior year was driven by the higher gross profit noted above and disciplined cost management.
A reconciliation of certain financial measures with the most directly comparable financial measures calculated in accordance with generally accepted accounting principles in
Operational Metrics
To provide transparency into our financial results, we are providing the following operational metrics.
As of | |||||||||||||||
June 30, | September 30, | December 31, | March 31, | June 30, | |||||||||||
2022 | 2022 | 2022 | 2023 | 2023 | |||||||||||
PACE census1: | |||||||||||||||
Medication census | 18,639 | 19,806 | 20,555 | 20,705 | 21,070 | ||||||||||
Technology-enabled solutions census | 50,763 | 52,230 | 53,430 | 54,135 | 55,804 | ||||||||||
Total PACE census | 50,763 | 52,230 | 53,430 | 54,135 | 55,804 | ||||||||||
Three Months Ended | |||||||||||||||
June 30, | September 30, | December 31, | March 31, | June 30, | |||||||||||
2022 | 2022 | 2022 | 2023 | 2023 | |||||||||||
PACE average revenue per participant per month: | |||||||||||||||
Medication average revenue per participant per month2 | $ | 1,036 | $ | 1,051 | $ | 1,056 | $ | 1,110 | $ | 1,100 | |||||
Technology-enabled solutions revenue per participant per month3 | 91 | 91 | 92 | 98 | 99 | ||||||||||
Total PACE average revenue per participant per month | 459 | 474 | 494 | 523 | 515 |
PACE backlog as of June 30, 2023, was valued at
Cancellation of Q2 Earnings Conference Call
In a separate press release, Tabula Rasa today announced that it entered into a definitive merger agreement to be acquired by Nautic Partners ("Nautic") for
About Tabula Rasa HealthCare
Tabula Rasa HealthCare (TRHC) (NASDAQ: TRHC) enables simplified and individualized care that improves the health of those we serve. We offer comprehensive pharmacy services that include personalized, precision medication management and delivery as well as a suite of clinical and business management tools that help health plans and at-risk provider groups optimize utilization and improve patient health. For more information, visit TRHC.
Non-GAAP Financial Measures
In addition to reporting certain financial information in accordance with GAAP, TRHC is also reporting gross profit, adjusted EBITDA, adjusted cost of revenue, adjusted gross profit, adjusted operating expenses, adjusted operating income (loss), and adjusted net income (loss), in each case from continuing operations, which are considered non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical measure of a company's performance or financial position that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. TRHC presents adjusted EBITDA and the other non-GAAP financial measures in this release because it considers each of them to be an important supplemental measure of performance. TRHC also intends to provide adjusted EBITDA and the other non-GAAP financial measures in this release as part of the Company's future earnings discussions and, therefore, their inclusion should provide consistency in the Company's financial reporting.
Adjusted EBITDA consists of net income (loss) plus certain other expenses, which include interest expense, provision for income tax, depreciation and amortization, change in fair value of contingent consideration receivable, impairment charges, business optimization expense, severance costs, executive transition costs, settlement costs, divestiture-related expense, transformation-related expense, stock-based compensation expense, and net loss on divestiture of businesses. TRHC considers business optimization expense to include employee and non-recurring vendor costs incurred related to its business optimization initiatives during 2022. TRHC considers severance costs to include severance costs related to the realignment of its resources. TRHC considers executive transition costs to include nonrecurring costs related to the hiring and onboarding of new named executive officers. TRHC considers settlement costs to include amounts payable by TRHC or reductions to amounts owed to TRHC as a result of a contractual settlement. TRHC considers divestiture-related expense to include non-recurring direct transaction costs. TRHC considers transformation-related expense to include non-recurring advisory fees incurred to assess a variety of strategic opportunities to increase shareholder value. TRHC considers net loss on divestiture of businesses to include the non-recurring net loss resulting from the sales of the DoseMe and SinfoníaRx businesses. TRHC uses adjusted EBITDA for planning purposes, including analysis of the Company's performance against prior periods, the preparation of operating budgets and determination of appropriate levels of operating and capital investments. TRHC believes that adjusted EBITDA provides additional insight for analysts and investors in evaluating the Company's financial and operational performance.
TRHC defines adjusted cost of revenue as cost of revenue as presented on the consolidated statements of operations less those certain other expenses which are added to operating income (loss) in calculating adjusted operating income (loss) (as described below), including stock-based compensation expense and such other expenses, in each case to the extent that they are included in cost of revenue. TRHC believes adjusted cost of revenue provides analysts and investors more accurate information regarding the actual cost of products and services provided by TRHC, excluding the impact of certain non-cash charges like stock-based compensation expense, and costs of revenue that are not recurring components of its core medication and technology-enabled solutions costs, for better comparability of its cost of revenue between periods.
TRHC defines gross profit as total revenue less total cost of revenue (exclusive of depreciation and amortization) as presented on the consolidated statements of operations. TRHC defines gross margin as gross profit as a percentage of total revenue. TRHC defines adjusted gross profit as total revenue less total cost of revenue (exclusive of depreciation and amortization) as presented on the consolidated statements of operations, excluding the impact of those certain other expenses which are added to operating income (loss) in calculating adjusted operating income (loss) (as described below), including stock-based compensation expense and such other expenses, in each case to the extent that they are included in cost of revenue. TRHC defines adjusted gross margin as adjusted gross profit as a percentage of total revenue. TRHC believes adjusted gross profit and adjusted gross margin provide analysts and investors more accurate information regarding its core profit margin on sales, excluding the impact of certain non-cash charges like stock-based compensation expense, and costs of revenue that are not recurring components of its core medication and technology-enabled solutions costs, for better comparability of gross profit between periods.
TRHC defines adjusted operating expenses as operating expenses as presented on the consolidated statements of operations plus or minus (as applicable) the impact those expenses added or subtracted from operating income (loss) in calculating adjusted operating income (loss), in each case to the extent they are included in operating expense. TRHC believes adjusted operating expenses provide analysts and investors more accurate information regarding its core operating expenses, which include research and development costs, sales and marketing costs, general and administrative costs, depreciation of property and equipment, and amortization of software development costs, excluding the impact of certain non-cash charges like amortization of intangible assets acquired in prior business acquisitions and stock-based compensation expense, and charges that are not recurring components of its core operating expenses, for better comparability between periods.
TRHC defines adjusted operating income (loss) as operating income (loss) plus or minus (as applicable) amortization of acquired intangibles, change in fair value of contingent consideration receivable, impairment charges, business optimization expense, severance costs, executive transition costs, divestiture-related expense, transformation-related expense, and stock-based compensation expense. The items included in the calculation of adjusted EBITDA are determined in calculating adjusted operating income (loss) in the same manner. TRHC believes adjusted operating income (loss) provides analysts and investors more accurate information regarding its core operating income (loss), excluding the impact of certain non-cash charges like amortization of intangible assets acquired in prior business acquisitions and stock-based compensation expense, and charges that are not recurring components of its core operating expenses, for better comparability between periods.
TRHC defines adjusted net income (loss) as net income (loss) plus or minus (as applicable) the impact of those expenses added or subtracted from operating income (loss) in calculating adjusted operating income (loss) along with the impact of amortization of debt discount and issuance costs, and the tax impact of all those items using an effective statutory tax rate on pre-tax income (loss) adjusted for those items. TRHC believes adjusted net income (loss) provides analysts and investors more accurate information regarding its core income (loss), excluding the impact of certain non-cash charges like amortization of intangible assets acquired in prior business acquisitions and stock-based compensation expense, and charges that are not recurring components of its core product and service costs or core operating expenses, for better comparability between periods.
In addition to the reasons given above for providing each of the non-GAAP financial measures included herein, TRHC believes each of these non-GAAP financials measures provides analysts and investors more accurate information for better comparability to other companies, although such other companies may calculate non-GAAP financial measures differently than TRHC.
Non-GAAP financial measures have limitations as an analytical tool. Investors are encouraged to review the reconciliations of adjusted EBITDA, adjusted cost of revenue, adjusted gross profit, adjusted operating expenses, adjusted operating income (loss), and adjusted net income (loss) to the most directly comparable GAAP measures provided in the accompanying tables.
Safe Harbor Statement
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended ("Exchange Act"), including our guidance regarding revenue from continuing operations and adjusted EBITDA from continuing operations. Forward-looking statements may be identified by words such as "believe," "will," "may," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "predict," "could," "potentially" or the negative of these terms or similar expressions. You should read these statements carefully because they discuss future expectations, contain projections of future results of operations or financial condition, or state other "forward-looking" information. These statements relate to, without limitation, our future plans, objectives, expectations, intentions, financial performance and the proposed acquisition of TRHC by Locke Buyer, LLC, an affiliate of Nautic, and the assumptions that underlie these statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Factors that might cause such a difference include, but are not limited to: (i) our expectations regarding industry and market trends, including the expected growth and continued structural change and consolidation in the market for healthcare in
Additional Information and Where to Find It
This press release may be deemed to be solicitation material in respect of the proposed acquisition of TRHC by Locke Buyer, LLC, an affiliate of Nautic. In connection with the proposed transaction, TRHC intends to file relevant materials with the SEC, including TRHC's proxy statement in preliminary and definitive form. INVESTORS AND STOCKHOLDERS OF TRHC ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH THE SEC, INCLUDING TRHC'S PROXY STATEMENT (IF AND WHEN AVAILABLE), BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and security holders are or will be able to obtain the documents (if and when available) free of charge at the SEC's website at www.sec.gov, or free of charge within the Investor Relations section of TRHC's website http://ir.trhc.com or upon request from TRHC's Investor Relations Department.
Participants in the Solicitation
TRHC and its directors, executive officers and other members of management and employees, under SEC rules, may be deemed to be "participants" in the solicitation of proxies from stockholders of TRHC in favor of the proposed transaction. Information about TRHC's directors and executive officers is set forth in TRHC's Proxy Statement on Schedule 14A for its 2023 Annual Meeting of Stockholders, which was filed with the SEC on April 28, 2023. To the extent holdings of TRHC's securities by its directors or executive officers have changed since the amounts set forth in such 2023 proxy statement, such changes have been or will be reflected on Initial Statements of Beneficial Ownership on Form 3 or Statements of Change in Ownership on Form 4 filed with the SEC. Additional information concerning the interests of TRHC's participants in the solicitation, which may, in some cases, be different than those of TRHC's stockholders generally, will be set forth in TRHC's proxy statement relating to the proposed transaction when it becomes available.
No Offer or Solicitation
This press release is not intended to and shall not constitute an offer to buy or sell or the solicitation of an offer to buy or sell any securities, or a solicitation of any vote or approval, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made in
TABULA RASA HEALTHCARE, INC. | ||||||
UNAUDITED CONSOLIDATED BALANCE SHEETS | ||||||
(In thousands) | ||||||
June 30, | December 31, | |||||
2023 | 2022 | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 62,811 | $ | 70,017 | ||
Restricted cash | 10,400 | 12,372 | ||||
Accounts receivable, net | 18,610 | 19,252 | ||||
Inventories | 8,659 | 6,566 | ||||
Prepaid expenses | 3,581 | 4,664 | ||||
Client claims receivable | 16,415 | 16,377 | ||||
Divestiture-related note receivable | 3,527 | — | ||||
Other current assets | 22,678 | 18,187 | ||||
Current assets of discontinued operations | — | 22,825 | ||||
Total current assets | 146,681 | 170,260 | ||||
Property and equipment, net | 9,369 | 9,158 | ||||
Operating lease right-of-use assets | 10,149 | 10,483 | ||||
Software development costs, net | 33,077 | 32,592 | ||||
Goodwill | 115,323 | 115,323 | ||||
Intangible assets, net | 35,129 | 38,326 | ||||
Contingent consideration receivable | — | 3,350 | ||||
Other assets | 6,209 | 4,657 | ||||
Total assets | $ | 355,937 | $ | 384,149 | ||
Liabilities and stockholders' deficit | ||||||
Current liabilities: | ||||||
Current operating lease liabilities | $ | 2,982 | $ | 2,708 | ||
Accounts payable | 20,623 | 19,459 | ||||
Client claims payable | 10,981 | 10,781 | ||||
Accrued expenses and other liabilities | 59,105 | 55,745 | ||||
Current liabilities of discontinued operations | — | 13,389 | ||||
Total current liabilities | 93,691 | 102,082 | ||||
Long-term debt, net of discount | 232,603 | 232,112 | ||||
Long-term debt – related party, net of discount | 88,709 | 88,522 | ||||
Noncurrent operating lease liabilities | 12,102 | 12,786 | ||||
Deferred income tax liability, net | 1,507 | 1,380 | ||||
Other long-term liabilities | 5,404 | 4,298 | ||||
Total liabilities | 434,016 | 441,180 | ||||
Stockholders' equity (deficit): | ||||||
Common stock | 3 | 3 | ||||
Treasury stock | (4,049) | (3,391) | ||||
Additional paid-in capital | 359,573 | 354,214 | ||||
Accumulated deficit | (433,606) | (407,857) | ||||
Total stockholders' deficit | (78,079) | (57,031) | ||||
Total liabilities and stockholders' deficit | $ | 355,937 | $ | 384,149 |
TABULA RASA HEALTHCARE, INC. | ||||||||||||
UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
(In thousands, except share and per share amounts) | ||||||||||||
Three Months Ended | Six Months Ended | |||||||||||
June 30, | June 30, | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
Revenue: | ||||||||||||
Medication revenue | $ | 69,626 | $ | 55,892 | $ | 138,376 | $ | 106,865 | ||||
Technology-enabled solutions revenue | 20,410 | 16,705 | 39,937 | 32,842 | ||||||||
Total revenue | 90,036 | 72,597 | 178,313 | 139,707 | ||||||||
Cost of revenue, exclusive of depreciation and amortization shown below: | ||||||||||||
Cost of medication revenue | 53,554 | 43,384 | 106,636 | 82,936 | ||||||||
Cost of technology-enabled solutions revenue | 13,953 | 13,247 | 28,395 | 26,416 | ||||||||
Total cost of revenue, exclusive of depreciation and amortization | 67,507 | 56,631 | 135,031 | 109,352 | ||||||||
Operating expenses: | ||||||||||||
Research and development | 1,777 | 3,243 | 3,056 | 7,208 | ||||||||
Sales and marketing | 2,732 | 2,172 | 5,185 | 4,821 | ||||||||
General and administrative | 17,599 | 15,150 | 34,176 | 31,028 | ||||||||
Change in fair value of contingent consideration receivable | 3,350 | — | 3,750 | — | ||||||||
Long-lived asset impairment charge | — | — | — | 4,062 | ||||||||
Depreciation and amortization | 6,103 | 5,489 | 12,303 | 11,231 | ||||||||
Total operating expenses | 31,561 | 26,054 | 58,470 | 58,350 | ||||||||
Loss from operations | (9,032) | (10,088) | (15,188) | (27,995) | ||||||||
Other income (expense): | ||||||||||||
Interest expense, net | (1,144) | (2,444) | (2,409) | (4,713) | ||||||||
Other income | 566 | — | 1,018 | — | ||||||||
Total other expense, net | (578) | (2,444) | (1,391) | (4,713) | ||||||||
Loss from continuing operations before income taxes | (9,610) | (12,532) | (16,579) | (32,708) | ||||||||
Income tax expense | 133 | 159 | 238 | 375 | ||||||||
Net loss from continuing operations | (9,743) | (12,691) | (16,817) | (33,083) | ||||||||
Net loss from discontinued operations, net of tax | (108) | (36,919) | (8,932) | (44,720) | ||||||||
Net loss | $ | (9,851) | $ | (49,610) | $ | (25,749) | $ | (77,803) | ||||
Net loss per share: | ||||||||||||
Net loss per share from continuing operations, basic and diluted | $ | (0.38) | $ | (0.53) | $ | (0.66) | $ | (1.38) | ||||
Net loss per share from discontinued operations, basic and diluted | — | (1.54) | (0.35) | (1.87) | ||||||||
Total net loss per share, basic and diluted | $ | (0.38) | $ | (2.07) | $ | (1.01) | $ | (3.25) | ||||
Weighted average common shares outstanding, basic and diluted | 25,422,032 | 23,959,726 | 25,333,137 | 23,913,050 |
TABULA RASA HEALTHCARE, INC. | ||||||
UNAUDITED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||
(In thousands) | ||||||
Six Months Ended | ||||||
June 30, | ||||||
2023 | 2022 | |||||
Cash flows from operating activities: | ||||||
Net loss | $ | (25,749) | $ | (77,803) | ||
Adjustments to reconcile net loss to net cash (used in) provided by operating activities: | ||||||
Depreciation and amortization | 12,303 | 18,562 | ||||
Amortization of deferred financing costs and debt discount | 678 | 939 | ||||
Deferred taxes | 127 | (368) | ||||
Stock-based compensation | 5,238 | 15,301 | ||||
Change in fair value of contingent consideration receivable | 3,750 | — | ||||
Impairment charges | 363 | 40,510 | ||||
Net loss on divestiture of businesses | 4,888 | — | ||||
Other noncash items | 292 | (54) | ||||
Changes in operating assets and liabilities, net of effect of divestitures: | ||||||
Accounts receivable, net | 514 | 2,979 | ||||
Inventories | (2,093) | (354) | ||||
Prepaid expenses and other current assets | (3,829) | (7,916) | ||||
Client claims receivables | (38) | (3,162) | ||||
Other assets | 3 | (769) | ||||
Accounts payable | (1,222) | 9,295 | ||||
Accrued expenses and other liabilities | 374 | 9,188 | ||||
Client claims payables | 200 | 353 | ||||
Other long-term liabilities | 554 | 2,139 | ||||
Net cash (used in) provided by operating activities | (3,647) | 8,840 | ||||
Cash flows from investing activities: | ||||||
Purchases of property and equipment | (1,310) | (471) | ||||
Software development costs | (7,187) | (17,870) | ||||
Proceeds from divestiture of businesses | 3,384 | — | ||||
Net cash used in investing activities | (5,113) | (18,341) | ||||
Cash flows from financing activities: | ||||||
Proceeds from exercise of stock options | 219 | 60 | ||||
Payments for employee taxes for shares withheld | (655) | — | ||||
Payments for debt financing costs | — | (350) | ||||
Borrowings on line of credit | — | 27,700 | ||||
Net cash (used in) provided by financing activities | (436) | 27,410 | ||||
Net (decrease) increase in cash, cash equivalents and restricted cash | (9,196) | 17,909 | ||||
Cash, cash equivalents and restricted cash, beginning of period | 82,407 | 15,706 | ||||
Cash, cash equivalents and restricted cash, end of period | $ | 73,211 | $ | 33,615 |
TABULA RASA HEALTHCARE, INC. | ||||||||||||
UNAUDITED RECONCILIATION OF NET LOSS TO ADJUSTED EBITDA | ||||||||||||
(In thousands) | ||||||||||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations | ||||||||||||
Net loss | $ | (9,851) | $ | (49,610) | $ | (25,749) | $ | (77,803) | ||||
Add: | ||||||||||||
Interest expense, net | 1,144 | 2,444 | 2,409 | 4,713 | ||||||||
Income tax expense | 133 | 159 | 238 | 375 | ||||||||
Depreciation and amortization | 6,103 | 5,489 | 12,303 | 11,231 | ||||||||
Change in fair value of contingent consideration receivable | 3,350 | — | 3,750 | — | ||||||||
Impairment charges | — | — | — | 4,062 | ||||||||
Business optimization expense | — | — | — | 787 | ||||||||
Severance costs | 385 | — | 776 | 575 | ||||||||
Executive transition | — | 150 | — | 150 | ||||||||
Divestiture-related expense | 352 | 1,414 | 1,368 | 1,534 | ||||||||
Transformation-related expense | 1,815 | — | 1,815 | — | ||||||||
Stock-based compensation expense | 2,770 | 5,092 | 5,200 | 12,795 | ||||||||
Loss from discontinued operations | 108 | 36,919 | 8,932 | 44,720 | ||||||||
Adjusted EBITDA from continuing operations | $ | 6,309 | $ | 2,057 | $ | 11,042 | $ | 3,139 | ||||
Adjusted EBITDA (loss) from discontinued operations | — | 1,117 | (2,676) | 2,557 | ||||||||
Total Adjusted EBITDA | $ | 6,309 | $ | 3,174 | $ | 8,366 | $ | 5,696 | ||||
Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||
2023 | 2022 | 2023 | 2022 | |||||||||
Reconciliation of Net Loss from Discontinued Operations, net of tax to | ||||||||||||
Net loss from discontinued operations, net of tax | $ | (108) | $ | (36,919) | $ | (8,932) | $ | (44,720) | ||||
Add: | ||||||||||||
Income tax (benefit) expense | (44) | (686) | 10 | (568) | ||||||||
Depreciation and amortization | — | — | — | 7,331 | ||||||||
Impairment charges | — | 35,608 | 363 | 36,448 | ||||||||
Net loss on divestiture of businesses | 152 | — | 4,888 | — | ||||||||
Severance costs | — | — | 957 | — | ||||||||
Settlement | — | 1,448 | — | 1,448 | ||||||||
Divestiture-related expense | — | 66 | — | 112 | ||||||||
Stock-based compensation expense | — | 1,600 | 38 | 2,506 | ||||||||
Adjusted EBITDA (loss) from discontinued operations | $ | — | $ | 1,117 | $ | (2,676) | $ | 2,557 |
TABULA RASA HEALTHCARE, INC. | |||||||||||||||||
UNAUDITED RECONCILIATION OF STATEMENT OF OPERATIONS TO NON-GAAP MEASURES | |||||||||||||||||
(In thousands) | |||||||||||||||||
Three Months Ended June 30, 2023 | |||||||||||||||||
Cost of | Gross | Gross | Operating | Operating | Net | ||||||||||||
Reconciliation of statement of operations to adjusted | |||||||||||||||||
Statement of operations amounts | $ | 67,507 | $ | 22,529 | 25.0 % | $ | 31,561 | $ | (9,032) | $ | (9,743) | ||||||
Adjustments: | |||||||||||||||||
Amortization of acquired intangibles | — | — | — | (1,598) | 1,598 | 1,598 | |||||||||||
Change in fair value of contingent consideration receivable | — | — | — | (3,350) | 3,350 | 3,350 | |||||||||||
Amortization of debt discount and issuance costs | — | — | — | — | — | 340 | |||||||||||
Severance costs | — | — | — | (385) | 385 | 385 | |||||||||||
Divestiture-related expense | — | — | — | (352) | 352 | 352 | |||||||||||
Transformation-related expense | — | — | — | (1,815) | 1,815 | 1,815 | |||||||||||
Stock-based compensation expense | (505) | 505 | 0.6 % | (2,265) | 2,770 | 2,770 | |||||||||||
Impact to income taxes | — | — | — | — | — | (129) | |||||||||||
Adjusted amounts | $ | 67,002 | $ | 23,034 | 25.6 % | $ | 21,796 | $ | 1,238 | $ | 738 | ||||||
Three Months Ended June 30, 2022 | |||||||||||||||||
Cost of | Gross | Gross | Operating | Operating | Net Loss | ||||||||||||
Reconciliation of statement of operations to adjusted | |||||||||||||||||
Statement of operations amounts | $ | 56,631 | $ | 15,966 | 22.0 % | $ | 26,054 | $ | (10,088) | $ | (12,691) | ||||||
Adjustments: | |||||||||||||||||
Amortization of acquired intangibles | — | — | — | (1,695) | 1,695 | 1,695 | |||||||||||
Amortization of debt discount and issuance costs | — | — | — | — | — | 471 | |||||||||||
Executive transition | — | — | — | (150) | 150 | 150 | |||||||||||
Divestiture-related expense | — | — | — | (1,414) | 1,414 | 1,414 | |||||||||||
Stock-based compensation expense | (793) | 793 | 1.1 % | (4,299) | 5,092 | 5,092 | |||||||||||
Impact to income taxes | — | — | — | — | — | 1,126 | |||||||||||
Adjusted amounts | $ | 55,838 | $ | 16,759 | 23.1 % | $ | 18,496 | $ | (1,737) | $ | (2,743) | ||||||
Six Months Ended June 30, 2023 | |||||||||||||||||
Cost of | Gross | Gross | Operating | Operating | Net | ||||||||||||
Reconciliation of statement of operations to adjusted | |||||||||||||||||
Statement of operations amounts | $ | 135,031 | $ | 43,282 | 24.3 % | $ | 58,470 | $ | (15,188) | $ | (16,817) | ||||||
Adjustments: | |||||||||||||||||
Amortization of acquired intangibles | — | — | — | (3,197) | 3,197 | 3,197 | |||||||||||
Change in fair value of contingent consideration receivable | — | — | — | (3,750) | 3,750 | 3,750 | |||||||||||
Amortization of debt discount and issuance costs | — | — | — | — | — | 678 | |||||||||||
Severance costs | — | — | — | (776) | 776 | 776 | |||||||||||
Divestiture-related expense | — | — | — | (1,368) | 1,368 | 1,368 | |||||||||||
Transformation-related expense | — | — | — | (1,815) | 1,815 | 1,815 | |||||||||||
Stock-based compensation expense | (984) | 984 | 0.5 % | (4,216) | 5,200 | 5,200 | |||||||||||
Impact to income taxes | — | — | — | — | — | 184 | |||||||||||
Adjusted amounts | $ | 134,047 | $ | 44,266 | 24.8 % | $ | 43,348 | $ | 918 | $ | 151 | ||||||
Six Months Ended June 30, 2022 | |||||||||||||||||
Cost of | Gross | Gross | Operating | Operating | Net Loss | ||||||||||||
Reconciliation of statement of operations to adjusted | |||||||||||||||||
Statement of operations amounts | $ | 109,352 | $ | 30,355 | 21.7 % | $ | 58,350 | $ | (27,995) | $ | (33,083) | ||||||
Adjustments: | |||||||||||||||||
Amortization of acquired intangibles | — | — | — | (3,389) | 3,389 | 3,389 | |||||||||||
Impairment charges | — | — | — | (4,062) | 4,062 | 4,062 | |||||||||||
Amortization of debt discount and issuance costs | — | — | — | — | — | 939 | |||||||||||
Business optimization expense | (433) | 433 | 0.3 % | (354) | 787 | 787 | |||||||||||
Severance costs | — | — | — | (575) | 575 | 575 | |||||||||||
Executive transition | — | — | — | (150) | 150 | 150 | |||||||||||
Divestiture-related expense | — | — | — | (1,534) | 1,534 | 1,534 | |||||||||||
Stock-based compensation expense | (1,918) | 1,918 | 1.4 % | (10,877) | 12,795 | 12,795 | |||||||||||
Impact to income taxes | — | — | — | — | — | 2,585 | |||||||||||
Adjusted amounts | $ | 107,001 | $ | 32,706 | 23.4 % | $ | 37,409 | $ | (4,703) | $ | (6,267) |
1 Defined as the number of PACE participants utilizing at least one of our solution lines.
2 This metric is calculated as quarterly medication revenue from PACE clients divided by quarterly member months.
3 This metric is calculated as quarterly technology-enabled solutions revenue from PACE clients across all solution lines divided by quarterly member months.
View original content to download multimedia:https://www.prnewswire.com/news-releases/tabula-rasa-healthcare-reports-second-quarter-2023-financial-results-301894280.html
SOURCE Tabula Rasa HealthCare, Inc.